Gilead Sciences Partners with U.S. Government to Reduce Drug Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Drug Cost Commitment: Gilead's three-year agreement with the U.S. government aims to reduce drug costs for Americans, ensuring that the U.S. no longer bears a disproportionate share of global healthcare expenses, thereby enhancing the company's competitiveness in the domestic market.
- Innovation Investment Plan: Gilead plans to invest $32 billion in U.S. manufacturing, R&D, and infrastructure over the next five years, which is projected to create over 3,000 direct and indirect jobs, further driving economic growth in the U.S.
- Global Health Leadership: This agreement not only reinforces America's leadership in global health and biomedical innovation but also complements Gilead's partnership with the U.S. Department of State to provide its HIV prevention drug at no profit to up to two million individuals in severely affected countries.
- Future Financial Impact: Gilead expects the financial impact of this agreement to be manageable in 2026 and beyond, indicating the company's pursuit of a balance between driving innovation and fulfilling social responsibilities, thereby enhancing its long-term sustainability.
GILD
$124.29+Infinity%1D
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 135.00 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 121.470
Low
105.00
Averages
135.00
High
150.00
Current: 121.470
Low
105.00
Averages
135.00
High
150.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
